RecruitingPHASE1, PHASE2NCT04094610
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Turning Point Therapeutics, Inc.
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Oral repotrectinib (TPX-0005)(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 25 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of California at Los Angeles, Los Angeles, California, United States
- Children's Hospital Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
- Local Institution - 2105, Orlando, Florida, United States
- Local Institution - 2120, Orlando, Florida, United States
- Children's Healthcare of Atlanta - Egleston Hospital, Atlanta, Georgia, United States
- Maine Medical Center, Scarborough, Maine, United States
- Dana Farber Cancer Institute., Boston, Massachusetts, United States
- Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
- Local Institution - 2110, New Brunswick, New Jersey, United States
- Local Institution - 2102, New York, New York, United States
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte, North Carolina, United States
- Local Institution - 2112, Cleveland, Ohio, United States
- Local Institution - 2114, Hershey, Pennsylvania, United States
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04094610 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- RECRUITINGPHASE1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT04925609Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsPrincess Maxima Center for Pediatric Oncology
See all trials for ALK-negative anaplastic large cell lymphoma →